HypercalcemiaMANAGEMENT

ENDOCRINE AND METABOLIC PRESENTATIONS · 12 SECTIONS

⚲

492 items

☷ Legend

⚲

Cardiovascular Presentations71▾

Respiratory Presentations52▾

Neurological Presentations83▾

Gastrointestinal Presentations74▾

Genitourinary and Reproductive Presentations48▾

Infectious Disease Presentations148▾

Trauma Presentations89▾

Toxicologic Presentations80▾

Psychiatric Presentations26▾

Musculoskeletal and Rheumatologic Presentations96▾

Dermatology Presentations23▾

Environmental and Exposure Presentations27▾

Hematologic and Oncologic Presentations36▾

Pediatric-Specific Presentations19▾

Endocrine and Metabolic Presentations45▾

Acute Porphyria Adrenal crisis Adrenal Insufficiency (Addisonian Crisis)Dehydration Diabetes Insipidus Diabetic Ketoacidosis (DKA)Euglycemic DKA (SGLT2 inhibitor)Galactosemia GLP-1 receptor agonist complications (retained gastric contents, aspiration risk)Homocystinuria Hypercalcemia Hyperkalemia Hypermagnesemia Hypernatremia Hyperosmolar Hyperglycemic State (HHS)Hypertensive emergency Hypertensive urgency Hypocalcemia Hypoglycemia Hypogonadism (Acute Presentation)Hypokalemia Hypomagnesemia Hyponatremia Hypoparathyroidism (Tetany)Insulin pump failure Maple Syrup Urine Disease (Crisis)Medium-Chain Acyl-CoA Dehydrogenase Deficiency (MCAD)Metabolic Acidosis Metabolic Alkalosis Myasthenia gravis crisis Myxedema coma Pellagra Pheochromocytoma (Crisis)Pituitary Apoplexy Pompe Disease (GSD II)Respiratory Acidosis Respiratory Alkalosis Scurvy SIADH Starvation Ketosis Tarui Disease (GSD VII)Thyroid storm Tyrosinemia Vitamin D Deficiency (Severe-Rickets)Von Gierke Disease (GSD I)

ENT and Maxillofacial Presentations27▾

Ophthalmologic Presentations19▾

Obstetric Presentations23▾

Systemic and Miscellaneous Presentations17▾

01Approach to the Critical Patient/attcp53

Immediate threats

›Initial stabilization priorities

›Airway protection triggers

›Depressed mental status with aspiration risk

›Refractory vomiting with inability to protect airway

›Circulation threats

›Dysrhythmia risk with shortened QT interval

›Hypotension from dehydration

›Shock with sepsis or malignancy

›Neurologic threats

›Seizure

›Coma

›Immediate escalation triggers

›Total calcium at or above 3.5 mmol/L

›Ionized calcium at or above 1.75 mmol/L

›New dysrhythmia

›Altered mental status

›Anuric acute kidney injury

Key targets and monitoring

›Monitoring and targets

›Cardiac monitoring

›Continuous telemetry for moderate to severe hypercalcemia

›ECG for QT interval and conduction changes

›Volume status targets

›Euvolemia

›Urine output target at or above 0.5 mL/kg/hour

›Electrolyte targets

›Potassium within reference range

02History/hx56

Presenting syndrome

›Symptom pattern and timing

›Neurocognitive

›Confusion

›Lethargy

›Psychosis

›Somnolence

›Gastrointestinal

›Nausea

›Vomiting

›Constipation

›Abdominal pain

›Pancreatitis symptoms

›Renal

›Polyuria

›Polydipsia

›Nephrolithiasis symptoms

›Musculoskeletal

›Weakness

›Bone pain

›Cardiac

›Palpitations

›Syncope

Risk factors and exposures

›Etiology clues

›Malignancy clues

›Weight loss

›Night sweats

03Physical Exam/exam32

Volume and mental status

›High yield exam domains

›Volume status

›Dry mucous membranes

›Orthostatic hypotension

›Jugular venous pressure estimate

›Peripheral edema absence or presence

›Mental status

›Orientation and attention

›Delirium features

›Somnolence

›Neuromuscular

›Proximal muscle strength

›Deep tendon reflexes

Malignancy and endocrine clues

›Etiology focused findings

›Malignancy signs

›Lymphadenopathy

›Cachexia

›Bone tenderness

›Thyrotoxicosis signs

›Tachycardia

›Tremor

›Hyperreflexia

›Granulomatous disease signs

›Pulmonary findings

›Skin lesions consistent with sarcoidosis

04Differential Diagnosis/ddx41

Hypercalcemia etiologies

›Cause categories

›PTH mediated

›Primary hyperparathyroidism

›ICD-10 E21.0

›SNOMED CT primary hyperparathyroidism

›Tertiary hyperparathyroidism

›ICD-10 E21.2

›SNOMED CT tertiary hyperparathyroidism

›Lithium associated hyperparathyroidism

›SNOMED CT drug induced hyperparathyroidism

›Malignancy associated

›Humoral hypercalcemia of malignancy

›PTHrP mediated

›Common tumors squamous cell lung and head and neck

›Osteolytic metastases

›Breast cancer

›Multiple myeloma

›Lymphoma with calcitriol excess

›Vitamin D mediated

›Vitamin D intoxication

›Granulomatous disease calcitriol excess

›Sarcoidosis

›Tuberculosis

›Medication and intake mediated

›Calcium alkali syndrome

›Thiazide associated hypercalcemia

›Vitamin A toxicity

05Laboratory Tests/lt40

Core confirmation and severity

›Essential labs

›Calcium measures

›Total calcium mmol/L

›Ionized calcium mmol/L for critical illness or hypoalbuminemia

›Repeat calcium after initial fluids when severe or symptomatic

›Renal and electrolytes

›Creatinine and urea

›Sodium

›Potassium

›Chloride

›Bicarbonate

›Magnesium

›Phosphate

›Acid base and dehydration

›Venous blood gas with pH and pCO2 mmHg when altered mental status

›Lactate when shock concern

Etiology workup

›First line etiologic labs

›PTH intact

›Elevated or inappropriately normal suggests PTH mediated

›Suppressed suggests PTH independent

›Albumin g/L

›Context for total calcium interpretation

›25 hydroxyvitamin D

›Elevated suggests intoxication

›PTHrP

›Consider when PTH suppressed and malignancy suspected

06Diagnostic Tests/dt39

Scoring Systems

›Severity and decision framework

›Severity grade

›Mild total calcium 2.6 to 3.0 mmol/L

›Moderate total calcium 3.0 to 3.5 mmol/L

›Severe total calcium above 3.5 mmol/L

›Symptom and organ involvement

›Neurologic dysfunction

›Cardiac dysrhythmia

›Acute kidney injury

›Refractory vomiting or ileus

›Dialysis trigger framework

›Severe hypercalcemia with renal failure

›Severe hypercalcemia with fluid overload limiting hydration

›Severe hypercalcemia with life threatening dysrhythmia

MRI

›MRI applications

›Malignancy assessment

›Spine MRI for cord compression symptoms

›Brain MRI for focal neurologic deficits

›Pituitary and parathyroid

›Not first line for hypercalcemia diagnosis

›Safety considerations

›Gadolinium avoidance when severe renal impairment

›CT applications

›Malignancy source evaluation

›CT chest for lung malignancy risk

07Disposition/dispo28

Level of care

›Admission and monitoring decisions

›ICU criteria

›Total calcium above 3.5 mmol/L

›Ionized calcium above 1.75 mmol/L

›Coma or seizures

›Dysrhythmia or hemodynamic instability

›Dialysis anticipated

›Ward criteria

›Symptomatic moderate hypercalcemia

›Acute kidney injury

›Need for IV bisphosphonate or denosumab monitoring

›Discharge criteria

›Mild hypercalcemia with minimal symptoms

›Reliable follow up within 24 to 72 hours

›No ECG abnormalities

›Stable renal function and hydration status

Consult and transfer triggers

›Specialty involvement

›Nephrology

›Severe renal impairment

›Dialysis consideration

›Endocrinology

›PTH mediated hypercalcemia

›Suspected parathyroid crisis

›Oncology

›Suspected hypercalcemia of malignancy

›Known cancer with recurrence concern

08Treatment/t99

Fluids and diuresis

›Volume management

›Isotonic crystalloid

›Initiate bolus 1 to 2 L when no fluid overload risk

›Reassess lungs and JVP after each bolus

›Urine output response monitoring

›Continuous infusion 100 to 200 mL/hour adjusted to euvolemia

›Lower rate when heart failure risk

›Higher rate when severe dehydration without overload

›Loop diuretic strategy

›If volume overload after rehydration then add loop diuretic

›Furosemide IV 20 to 40 mg

›Repeat dosing based on urine output and volume status

›Electrolyte monitoring for hypokalemia and hypomagnesemia

Rapid temporizing agent

›Calcitonin

›Indications

›Severe symptomatic hypercalcemia

›Bridge while bisphosphonate or denosumab takes effect

›Dosing

›Salmon calcitonin 4 IU/kg SC or IM every 12 hours

›If inadequate response then 8 IU/kg SC or IM every 6 to 12 hours

›Typical onset 4 to 6 hours

›Tachyphylaxis after 24 to 48 hours

›Adverse effects

›Nausea

›Flushing

›Hypersensitivity risk

Anti-resorptive therapy

›Intravenous bisphosphonates

›General principles

›Onset 24 to 48 hours

›Nadir effect 2 to 4 days

›Renal toxicity risk

›Avoid or adjust in severe renal impairment

›Zoledronic acid

›Dose 4 mg IV

›Infusion time at least 15 minutes

›Re dose consideration at 7 days if refractory per protocol

›Osteonecrosis of jaw risk with repeated dosing

›Pamidronate

›Dose 60 mg IV for moderate hypercalcemia

›Infusion time 2 to 4 hours

›Renal monitoring

›Dose 90 mg IV for severe hypercalcemia

›Infusion time 2 to 6 hours

›Renal monitoring

›Denosumab

›Indications

›Hypercalcemia of malignancy refractory to bisphosphonate

›Severe renal impairment limiting bisphosphonate use

›Dosing

›Denosumab 120 mg SC

›Repeat day 8

›Repeat day 15

›Then every 4 weeks

›Monitoring

›Hypocalcemia risk after treatment

›Magnesium and phosphate monitoring

Etiology specific therapies

›Glucocorticoids

›Indications

›Calcitriol mediated hypercalcemia

›Granulomatous disease

›Lymphoma associated hypercalcemia

›Dosing options

›Prednisone 40 mg PO daily

›Typical course 3 to 7 days with reassessment

›Hydrocortisone 100 mg IV every 8 hours when severe illness

›Calcimimetic

›Cinacalcet

›Indications

›Parathyroid carcinoma

›Severe primary hyperparathyroidism when surgery delayed

›Dosing

›Cinacalcet 30 mg PO twice daily

›Titration every 2 to 4 weeks based on calcium response

›Medication and intake reversal

›Thiazide discontinuation

›Alternate antihypertensive planning

›Lithium review

›Psychiatry coordination when needed

›Calcium and vitamin D hold

›Stop calcium carbonate and high dose vitamin D until evaluated

Dialysis and advanced rescue

›Renal replacement therapy

›Indications

›Severe hypercalcemia with renal failure and oliguria

›Severe hypercalcemia with fluid overload limiting hydration

›Severe hypercalcemia with life threatening dysrhythmia

›Technique considerations

›Low calcium dialysate protocol per nephrology

›Concurrent management of phosphate and magnesium

Evidence levels and guideline notes

›Evidence and guidance summary

›Endocrine Society guideline for hypercalcemia of malignancy

›IV bisphosphonate or denosumab recommended over no antiresorptive therapy

›Recommendation 1 with very low certainty notation 1⊕◯◯◯

›Denosumab suggested over IV bisphosphonate in adults with hypercalcemia of malignancy

›Recommendation 2 with very low certainty notation 2⊕◯◯◯

›Severe hypercalcemia of malignancy combination calcitonin plus bisphosphonate or denosumab suggested

›Recommendation 3 with very low certainty notation 2⊕◯◯◯

›ACEP Level C style consensus in ED practice

›Aggressive isotonic fluid resuscitation for severe symptomatic hypercalcemia

›Calcitonin as rapid temporizing agent while antiresorptives take effect

09Special Populations/sp35

Pregnancy

›Pregnancy considerations

›Maternal risks

›Dehydration and kidney injury risk

›Pancreatitis risk

›Dysrhythmia risk

›Fetal and neonatal risks

›Neonatal hypocalcemia after maternal hypercalcemia

›Growth restriction risk in severe disease

›Diagnostics

›Ionized calcium preferred when albumin altered

›PTH based etiologic split

›Treatment considerations

›Isotonic fluids as first line

›Calcitonin as short term option

›Bisphosphonate use only with specialist input

Geriatric

›Older adult considerations

›Atypical presentation

›Delirium as primary symptom

›Falls and weakness

›Treatment modifications

›Slower fluid resuscitation with frequent lung reassessment

›Higher risk of renal injury from bisphosphonates

›Etiology prevalence

›Malignancy and primary hyperparathyroidism common

Pediatrics

›Pediatric considerations

10Background/b37

Epidemiology

›Frequency and settings

›Common outpatient causes

›Primary hyperparathyroidism

›Common inpatient causes

›Hypercalcemia of malignancy

›Malignancy association

›Hypercalcemia of malignancy affects a meaningful minority of cancer patients

›High short term morbidity and mortality association

Pathophysiology

›Mechanisms

›PTH mediated

›Increased bone resorption

›Increased renal calcium reabsorption

›Increased calcitriol production

›PTHrP mediated

›PTH receptor activation

›Renal phosphate wasting

›Calcitriol mediated

›Increased intestinal calcium absorption

›Granuloma macrophage 1 alpha hydroxylase activity

›Calcium alkali syndrome

›Increased intake plus alkalosis

›Reduced renal calcium excretion

Therapeutic Considerations

›Treatment rationale

›Isotonic fluids

›Restores GFR and calciuresis

11Patient Discharge Instructions/pdi18

copy discharge instructions

›Home care and follow up

›Hydration

›Oral fluids goal pale yellow urine unless fluid restriction

›Avoid dehydration from exercise or illness

›Medication and supplement changes

›Stop calcium supplements unless explicitly prescribed

›Stop high dose vitamin D until follow up

›Avoid thiazide diuretics unless clinician directs otherwise

›Follow up plan

›Repeat calcium and kidney function within 24 to 72 hours when mild

›Endocrinology or primary care follow up for PTH evaluation

›Return now

›Confusion or severe sleepiness

›Fainting or palpitations

›Severe vomiting or inability to keep fluids down

›Severe weakness or inability to walk

›Little or no urine output

›New severe abdominal pain

12References/r14

Clinical guidelines and consensus

›Key guidance sources

›Endocrine Society Clinical Practice Guideline for Treatment of Hypercalcemia of Malignancy in Adults

›Recommendations for IV bisphosphonate or denosumab

›Recommendation for calcitonin combination in severe hypercalcemia of malignancy

›Emergency guidance for acute hypercalcaemia in adults from endocrine specialty societies

›Initial management with isotonic fluids

›Use of IV bisphosphonate and calcitonin in severe cases

›Institutional inpatient algorithms for acute hypercalcemia management

›Fluid bolus then infusion strategy

›Monitoring guidance for fluid overload risk

Evidence based sources

›Supporting evidence examples

›Randomized trial evidence comparing zoledronic acid versus pamidronate for hypercalcemia of malignancy

›Systematic review supporting Endocrine Society hypercalcemia of malignancy guideline

›Review evidence on limitations of albumin corrected calcium formulas in hypoalbuminemia

Learn More: Hypercalcemia→

Comprehensive Clinical Review

Structured, evidence-informed, long-form analysis for deeper understanding.

Evidence & Review

Reviewed by SymptomDx Medical Team · Last reviewed August 18, 2026

SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.